Cargando…

Cardiovascular Injury Due to SARS-CoV-2

PURPOSE OF REVIEW: The world is currently facing the largest global health crisis since the early 1900s due to a novel coronavirus. While SARS-CoV-2 infection causes predictable symptoms in COVID-19 patients, including upper respiratory distress and fever, the heterogeneity of manifestations is surp...

Descripción completa

Detalles Bibliográficos
Autores principales: Bugert, Christina L., Kwiat, Victoria, Valera, Isela C., Bugert, Joachim J., Parvatiyar, Michelle S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934983/
https://www.ncbi.nlm.nih.gov/pubmed/33717830
http://dx.doi.org/10.1007/s40588-021-00160-0
_version_ 1783660922035765248
author Bugert, Christina L.
Kwiat, Victoria
Valera, Isela C.
Bugert, Joachim J.
Parvatiyar, Michelle S.
author_facet Bugert, Christina L.
Kwiat, Victoria
Valera, Isela C.
Bugert, Joachim J.
Parvatiyar, Michelle S.
author_sort Bugert, Christina L.
collection PubMed
description PURPOSE OF REVIEW: The world is currently facing the largest global health crisis since the early 1900s due to a novel coronavirus. While SARS-CoV-2 infection causes predictable symptoms in COVID-19 patients, including upper respiratory distress and fever, the heterogeneity of manifestations is surprising. This review focuses on direct and indirect causes of myocardial injury in COVID-19 patients and highlights current knowledge, treatment strategies, and outstanding questions in the field. RECENT FINDINGS: Data are emerging that highlight the extent of cardiovascular involvement in COVID-19 patients, including evidence that SARS-CoV-2 causes myocarditis and increases cardiac risk. The incidence of cardiac injury is much greater in patients with severe disease presentation and those in intensive care. SUMMARY: During the past year, COVID-19 patient mortality rates have improved due to tailored pharmacological treatments and patient management strategies that address the unique presentation of symptoms, which will hopefully also reduce the incidence of cardiac injury.
format Online
Article
Text
id pubmed-7934983
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-79349832021-03-08 Cardiovascular Injury Due to SARS-CoV-2 Bugert, Christina L. Kwiat, Victoria Valera, Isela C. Bugert, Joachim J. Parvatiyar, Michelle S. Curr Clin Microbiol Rep Virology (S Li and K Parvatiyar, Section Editors) PURPOSE OF REVIEW: The world is currently facing the largest global health crisis since the early 1900s due to a novel coronavirus. While SARS-CoV-2 infection causes predictable symptoms in COVID-19 patients, including upper respiratory distress and fever, the heterogeneity of manifestations is surprising. This review focuses on direct and indirect causes of myocardial injury in COVID-19 patients and highlights current knowledge, treatment strategies, and outstanding questions in the field. RECENT FINDINGS: Data are emerging that highlight the extent of cardiovascular involvement in COVID-19 patients, including evidence that SARS-CoV-2 causes myocarditis and increases cardiac risk. The incidence of cardiac injury is much greater in patients with severe disease presentation and those in intensive care. SUMMARY: During the past year, COVID-19 patient mortality rates have improved due to tailored pharmacological treatments and patient management strategies that address the unique presentation of symptoms, which will hopefully also reduce the incidence of cardiac injury. Springer International Publishing 2021-03-05 2021 /pmc/articles/PMC7934983/ /pubmed/33717830 http://dx.doi.org/10.1007/s40588-021-00160-0 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Virology (S Li and K Parvatiyar, Section Editors)
Bugert, Christina L.
Kwiat, Victoria
Valera, Isela C.
Bugert, Joachim J.
Parvatiyar, Michelle S.
Cardiovascular Injury Due to SARS-CoV-2
title Cardiovascular Injury Due to SARS-CoV-2
title_full Cardiovascular Injury Due to SARS-CoV-2
title_fullStr Cardiovascular Injury Due to SARS-CoV-2
title_full_unstemmed Cardiovascular Injury Due to SARS-CoV-2
title_short Cardiovascular Injury Due to SARS-CoV-2
title_sort cardiovascular injury due to sars-cov-2
topic Virology (S Li and K Parvatiyar, Section Editors)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934983/
https://www.ncbi.nlm.nih.gov/pubmed/33717830
http://dx.doi.org/10.1007/s40588-021-00160-0
work_keys_str_mv AT bugertchristinal cardiovascularinjuryduetosarscov2
AT kwiatvictoria cardiovascularinjuryduetosarscov2
AT valeraiselac cardiovascularinjuryduetosarscov2
AT bugertjoachimj cardiovascularinjuryduetosarscov2
AT parvatiyarmichelles cardiovascularinjuryduetosarscov2